Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
-
SciScore for 10.1101/2021.04.13.439482: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Mouse model: Animal experiments were carried out in compliance with approval from the Animal Care and Use Committee of Moderna Inc. Randomization 34-36 Experiments were neither randomized nor blinded. Blinding 34-36 Experiments were neither randomized nor blinded. Power Analysis not detected. Sex as a biological variable Female BALB/c mice (6-8 weeks old; Charles River Laboratories) were used. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources To make SARS-CoV-2 full-length S pseudotyped recombinant VSV-ΔG-firefly luciferase virus, BHK-21/WI-2 cells (Kerafast) were transfected with the S expression plasmid and … SciScore for 10.1101/2021.04.13.439482: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: Mouse model: Animal experiments were carried out in compliance with approval from the Animal Care and Use Committee of Moderna Inc. Randomization 34-36 Experiments were neither randomized nor blinded. Blinding 34-36 Experiments were neither randomized nor blinded. Power Analysis not detected. Sex as a biological variable Female BALB/c mice (6-8 weeks old; Charles River Laboratories) were used. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources To make SARS-CoV-2 full-length S pseudotyped recombinant VSV-ΔG-firefly luciferase virus, BHK-21/WI-2 cells (Kerafast) were transfected with the S expression plasmid and subsequently infected with VSVΔG-firefly-luciferase as previously described. BHK-21/WI-2suggested: RRID:CVCL_HB78)The virus-serum mix was subsequently used to infect A549-hACE2-TMPRSS2 cells for 18 h at 37°C before adding ONE-Glo reagent (Promega) for measurement of luciferase signal (relative luminescence unit; RLU). A549-hACE2-TMPRSS2suggested: NoneExperimental Models: Organisms/Strains Sentences Resources Female BALB/c mice (6-8 weeks old; Charles River Laboratories) were used. BALB/csuggested: NoneSoftware and Algorithms Sentences Resources Female BALB/c mice (6-8 weeks old; Charles River Laboratories) were used. Charles River Laboratoriessuggested: (Charles River Laboratories, RRID:SCR_003792)Titers were determined using a 4-parameter logistic curve fit in GraphPad Prism (GraphPad Software, Inc.) and defined as the reciprocal dilution at approximately OD450 = 1.0 (normalized to a mouse standard on each plate). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Several potential limitations to the current study should be highlighted. Sera from mRNA-1273 vaccinated NHP or human sera was shown to have 6-8 fold reduced neutralizing activity against the B.1.351 variant SARS-CoV-2 in several assessments, although the level of neutralization remained at levels that are predicted to be protective.26,39 Results in this study, however, showed that after the primary series of mRNA-1273, only a 2-fold reduced neutralization against the B.1.351 virus was evident 2 weeks after the second dose. A 6.6-fold reduction was seen at day 212, more relevant to what has been measured from human sera. Further studies in animal species more predictive of responses in humans such as non-human primates as well as clinical studies in humans are ongoing. Further, only mRNA-1273.351 was evaluated as a third dose. The ability of the multivalent mRNA-1273.211 to boost immunity against both the D614G and B.1.351 viruses has not yet been assessed, although this type of cross-variant boosting is expected. Finally, very little antibody waning was measured in the 7-month evaluation of antibody levels in mice prior to the delivery of the boosting dose. This level of durability may not be reflective of that measured in NHPs or humans.40 The emergence of SARS-CoV-2 variants and the ability of the virus to partially overcome natural or vaccine-induced immunity served as a call to action. Not only are continued vaccination efforts needed to prevent the emergence of future V...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-